Publications by authors named "S E Rapecki"
Rheumatoid arthritis (RA) is an immune-mediated, chronic inflammatory condition. With modern therapeutics and evidence-based management strategies, achieving sustained remission is increasingly common. To prevent complications associated with prolonged use of immunosuppressants, drug tapering or withdrawal is recommended.
View Article and Find Full Text PDFArticle Synopsis
- * The study found that rozanolixizumab can bind to Fc gamma receptors (FcγRs) and mediate a process called antibody bipolar bridging, which influences macrophage surface proteins, but this effect can be inhibited by the presence of human IgG.
- * Importantly, experiments showed that rozanolixizumab's binding to its receptors did not trigger cellular activation, raising questions about its actual engagement with FcγRs in clinical settings where competing IgG is present.
Bispecific antibodies can uniquely influence cellular responses, but selecting target combinations for optimal functional activity remains challenging. Here we describe a high-throughput, combinatorial, phenotypic screening approach using a new bispecific antibody target discovery format, allowing screening of hundreds of target combinations. Simple mixing of Fab-fusion proteins from a diverse library enables the generation of thousands of screen-ready bispecific antibodies for high-throughput, biologically relevant assays.
View Article and Find Full Text PDFArticle Synopsis
- Interleukin (IL)-17A plays a critical role in inflammation and is a target for treatments using monoclonal antibodies, particularly in diseases like psoriasis and psoriatic arthritis.
- Researchers developed a humanized antibody, 496.g3, which improved the binding capability to both IL-17A and IL-17F, demonstrating greater efficacy than existing treatments.
- Early clinical studies of 496.g3, now called bimekizumab, show promising results in treating various IL-17-mediated inflammatory diseases, indicating potential benefits of targeting both IL-17A and IL-17F simultaneously.
B cells are postulated to be central in seropositive rheumatoid arthritis (RA). Here, we use exploratory mass cytometry (n = 23) and next-generation sequencing (n = 19) to study B-cell repertoire shifts in RA patients. Expression of several B-cell markers were significantly different in ACPA RA compared to healthy controls, including an increase in HLA-DR across subsets, CD22 in clusters of IgM B cells and CD11c in IgA memory.
View Article and Find Full Text PDF